Related Experiment Video
Updated: Aug 4, 2025

Platelet-Rich Plasma Lysate for Treatment of Eye Surface Diseases
Published on: August 2, 2022
Tildrakizumab in Complex Psoriatic Patients: An Experience in Emilia-Romagna (Italy)
Federico Bardazzi1,2, Filippo Viviani1,2, Bianca Maria Piraccini1,2
118508 Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Background:
IL-23 inhibitors are the latest class of biologic drugs approved for moderate-to-severe psoriasis.
Objectives:
to investigate real-life safety and efficacy of tildrakizumab.
Methods:
demographic data, medical history, psoriasis disease history, PASI, DLQI, BSA, NAPSI were recorded at weeks 0, 12, 24, 36.
Results:
PASI, BSA, DLQI and NAPSI all decreased rapidly during the 36 week follow-up period. PASI score reduced from 12.28 to 4.65 by week 12, followed by a further decrease to 1.18 at week 36 Multiple logistic regression showed that smoking, BMI ≥30, ≥3 comorbidities, previous systemic traditional or biologic drugs, psoriatic arthritis nor difficult-to-treat areas influenced the reduction of PASI and NAPSI scores during treatment with tildrakizumab (P > .05).
Conclusions:
we assessed a good performance of tildrakizumab in patients with multiple comorbidities, multi-failure, elderly patients, and in subjects with psoriatic arthritis.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Ulcerative Colitis in IBD
Rheumatic Heart Disease III: Medical Management

